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Background: Bronchodilators are a mainstay of treatment for patients with airflow obstruction. We hypothesized
that patients with obesity and no objective documentation of airflow obstruction are inappropriately treated with
bronchodilators.
Methods: Spirometric results and medical records of all patients with body mass index >30 kg/m2 who were
referred for testing between March 2010 and August 2011 were analyzed.
Results: 155 patients with mean age of 52.6 ± (SE)1.1 y and BMI of 38.7 ± 0.7 kg/m2 were studied. Spirometry
showed normal respiratory mechanics in 62 (40%), irreversible airflow obstruction in 36 (23.2%), flows suggestive of
restriction in 35 (22.6%), reversible obstruction, suggestive of asthma in 11 (7.1%), and mixed pattern (obstructive
and restrictive) in 6 (3.9%). Prior to testing, 45.2% (28 of 62) of patients with normal spirometry were being treated
with medications for obstructive lung diseases and 33.9% (21 of 62) continued them despite absence of airflow
obstruction on spirometry. 60% (21 of 35) of patients with a restrictive pattern in their spirometry received
treatment for obstruction prior to spirometry and 51.4% (18 of 35) continued bronchodilator therapy after
spirometric testing. There was no independent association of non-indicated treatment with spirometric results, age,
BMI, co-morbidities or smoking history. All patients with airflow obstruction on testing who were receiving
bronchodilators before spirometry continued to receive them after testing.
Conclusion: A substantial proportion of patients with obesity referred for pulmonary function testing did not have
obstructive lung disease, but were treated nonetheless, before and after spirometry demonstrating absence of
airway obstruction.
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Previous studies have demonstrated over-diagnosis of
asthma and chronic obstructive pulmonary disease
(COPD) in adult populations [1-3]. There are also data
to suggest that obese patients are more likely to report
respiratory symptoms – especially dyspnea - more than
non-obese patients [4]. Accordingly, we hypothesized
that obese patients with respiratory complaints prompt-
ing pulmonary function tests would be at risk of
mischaracterization and persistent, non-indicated treat-
ment of obstructive lung disease.* Correspondence: constantinemanthous@gmail.com
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The study protocol was exempted from review as set forth
in the Code of Federal Regulations, 45 CFR 46.101(b) by
the Bridgeport Hospital Institutional Review Board. Spiro-
metric tests, conducted at Bridgeport Hospital between
March 2010 and August 2011, were retrieved from
the laboratory’s electronic database. Spirometry was per-
formed according American Thoracic and European
Respiratory Society (ATS-ERS) guidelines [5-7] and pa-
tients were instructed not to take bronchodilators starting
on the night prior to study. Metacholine broncho-provo-
cation tests were performed when requested by the refer-
ring physician. Spirometric tests that were not considered
acceptable by the reading pulmonologist were not en-
rolled. Interpretations of pulmonary function tests (PFTs)td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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certified pulmonologists who applied ATS-ERS standards
and guidelines [8]. Per these standards, obstruction is de-
fined as reduced forced expired volume in 1 second: vital
capacity (FEV1/VC) ratio below the 5th percentile of the
predicted value. Asthma is defined as obstruction and in-
crease in FEV1 and/or forced vital capacity (FVC) of ≥12%
from baseline in response to bronchodilator, or a positive
metacholine challenge test. A restrictive defect is defined
as total lung capacity (TLC) below the 5th percentile of
the predicted value. In the absence of measured lung
volumes, a restrictive ventilatory defect is suggested by a
reduced VC when FEV1/VC is increased (85–90%) and
the flow–volume curve demonstrates a convex pattern. A
“mixed pattern” is defined as both FEV1/VC ratio and
TLC below the 5th percentiles of their predicted values
[8]. In our study, abnormal PFTs that could not be classi-
fied in any of the above categories using ATS-ERS stan-
dards and guidelines were categorized as inconclusive.
Our lab does not measure VC routinely and the FVC was
used for interpretation of function tests.
The following data were extracted from electronic
medical records for all patients with body mass index
(BMI) > 30 kg/m2: demographics, co-morbidities, smo-
king history, pre-testing pulmonary diagnosis, interpre-
tation of spirometry, medications prior to testing, and
medications following testing (≥6 months later). Patients
were excluded if they had no hospital medical records
before and after the spirometry. We followed all the
patients for a minimum of 6 months after spirometry.
Logistic regression analysis was performed using Epi
Info™ to identify variables associated with perseverant
treatment of patients with bronchodilators in the ab-
sence of airflow obstruction on spirometry. Age, BMI,Figure 1 Selection of participants and diagnoses according to pulmocongestive heart failure (CHF), diabetes mellitus (DM),
hypertension (HTN), sex and smoking were chosen as
independent variables for modeling based on biological
plausibility and/or if they demonstrated an association
with inappropriate bronchodilator treatment in univa-
riate analyses.
A P < 0.05 signified statistical significance.
Results
36 of 244 spirometries were considered technically un-
acceptable by the reading pulmonologist and were ex-
cluded from analysis. 208 patients with BMI > 30 kg/m2
had acceptable spirometry during the study period, of
whom 53 patients had no electronic records ≥6 months
after testing (Figure 1). Of the remaining 155 patients,
84 (55%) were female, mean age was 52.6 ± (SE)1.1 y and
BMI was 38.7 ± 0.7 kg/m2. 97 (62.8%) had hypertension,
56 (36.1%) diabetes mellitus and 13 (8.4%) congestive
heart failure (Table 1). The most common reasons for
spirometry were dyspnea (n = 43; 27.7%) and “COPD”
(43; 27.7%), followed by “asthma” in (19; 12.3%), cough
(13; 8.4%), pre-operative evaluation (12; 7.7%), not speci-
fied (10; 6.5%), restrictive lung disease (8; 5.2%) and ob-
structive sleep apnea (7; 4.5%) (Figure 2). Fifty-seven
patients also had measurements of lung volumes (which
were interpreted in conjunction with spirometry).
Patients demonstrated a mean FEV1 of 66.6 ± 1.4%,
mean FVC of 65.9 ± 1.3% with an average FEV1/FVC
ratio of 77.8% and a TLC of 82.7 ± 3.7% of the predicted
values (Table 2). Please refer to Table 2 for lung function
descriptive statistics for each group.
Pulmonary testing was normal in 62 (40%), showed irre-
versible airflow obstruction in 36 (23.2%), restriction in 35
(22.6%), reversible obstruction suggestive of asthma in 11nary function tests.
Table 1 Characteristics of patients
Characteristics
Age (years) 52.6 ± 1.1
Body mass index (kg/m2) 38.7 ± 0.7
Female 84 (54.8%)
Hypertension 97 (62.8%)
Diabetes mellitus 56 (36.1%)
Congestive heart failure 13 (8.4%)
Active smokers 48 (23.1%)
Age and body mass index are presented as means and standard error. Gender,
co-morbidities and smoking habit are presented in numbers and percentages
of the study population.
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6 (3.9%) and inconclusive studies in 5 (3.2%) patients
(Figure 1). Prior to testing, 45.5% (28 of 62) of patients
with normal spirometry were being treated with medica-
tions for obstructive lung diseases; 15 (53.6%) and 13
(46.4%) of these 28 individuals were misdiagnosed with
asthma and COPD, respectively. 33.9% (21 of 62) of these
patients continued treatments with medications for ob-
structive lung diseases despite absence of airflow obstruc-
tion on spirometry. 60% (21 of 35) of patients with a
restrictive pattern in their spirometry received treatment
for obstruction prior to spirometry; 10 (47.6%) and 6
(25.6%) of these patients were misdiagnosed as asthma
and COPD, respectively. And 86% continued broncho-
dilator therapy despite spirometry results that did not
demonstrate airway obstruction (Figure 3).
There was no independent association of non-indi-
cated treatment with spirometric results, age, BMI, co-
morbidities or smoking (Table 3). All patients with
airflow obstruction on testing who were receiving bron-
chodilators before spirometry (28 of 36 with irreversibleFigure 2 Reason for the referral to spirometric testing given by
referring physicians. Chronic obstructive lung disease (COPD).
Pre-operative evaluation (Preop). OSA (Obstructive sleep apnea).and 9 of 11 with reversible obstruction) continued to re-
ceive them after testing (Figure 3). Medications used to
treat patients with normal tests included beta2-agonists
in 40.3% (25 of 62), inhaled corticosteroids in 16.1%
(10), anticholinergics in 14.5% (9), systemic corticoste-
roids in 8.1% (5) and leukotriene modifier in 1.6% (1).
Individuals with restrictive pattern were prescribed beta-
2 agonists in 54.3% (19 of 35), inhaled steroids in 28.6%
(10), anticholinergics in 14.3% (5), and (short-course)
systemic corticosteroids 14.3% (5) (Table 4).
Discussion
This observational cohort study demonstrates that half
of all obese patients referred for spirometry were treated
empirically with bronchodilators before testing, and that
even after spirometry demonstrated the absence of air-
flow obstruction 40% (39 of 97) continued to be pre-
scribed therapies directed at obstructive lung disease 6
or more months after testing. Misdiagnosis of obstruc-
tive lung disease is not uncommon. Lindesmith and
colleagues reported that many Canadian community cli-
nicians diagnosed obstructive lung disease on clinical
grounds; 41% of (37 of 90) patients were labeled as asth-
matic but failed to meet diagnostic criteria [2]. As in our
study, 62% of these misdiagnosed patients continued to
receive inhaled beta-agonists, while 43% received inhaled
glucocorticoids. In two separate studies, 30% of patients
diagnosed with asthma on clinical grounds did not sat-
isfy pulmonary function test criteria for obstruction
[3,9]. In another study, 10-41% of patients in primary
care offices used inhaled steroids for a clinical diagnosis
of asthma or COPD without spirometric evidence to
support the diagnoses [1].
We are unaware of a previous study that has focused
on obese patients receiving spirometric testing. We fo-
cused on this population because they comprise a large
demographic who commonly present with respiratory
complaints [4], most often related to restrictive respi-
ratory mechanics [10] and increased oxygen cost of
breathing [4], and who might be – at least in theory –
more vulnerable to complications of unnecessary poly-
pharmacy. While some studies have suggested an inverse
relationship of BMI and FEV1 [11,12] and an association
of obesity and obstructive lung diseases [13,14], the fre-
quency with which dyspnea is caused by obstructive vs.
restrictive physiology in obese patients has not been
well-studied. Obese patients are more likely to report
respiratory symptoms – especially dyspnea -more than
non-obese patients [4]. Truncal obesity can reduce chest
wall compliance, and respiratory muscle strength and
function [15]. Accordingly, we hypothesized that obese
patients with respiratory complaints prompting pul-
monary function tests would be at risk of mischarac-
terization and persistent, non-indicated treatment of
Table 2 Lung function descriptive statistics
Total Asthma COPD Mixed Normal Restriction
FEV1% 66.6 ± 1.4 59.9 ± 6.4 55.2 ± 2.5 50.1 ± 5.7 92.8 ± 1.6 66.6 ± 2.8
FVC% 65.9 ± 1.3 74.3 ± 5.3 72.8 ± 2.6 61.5 ± 7.6 92.5 ± 1.6 65.9 ± 2.7
FEV1/FVC% 77.8 ± 1.1 64 ± 5.5 58.9 ± 1.9 64.8 ± 3.5 81.5 ± 0.9 77.8 ± 2.4
TLC%* 82.7 ± 3.7 97.2 ± 6.4 101.5 ± 7.6 66.6 ± 4.6 100.2 ± 13.4 69.1 ± 1.4
Values are presented as means and standard error. FEV1, FVC and TLC are expressed as percentages of the predicted values. FEV1, forced expired volume in
1 second; FVC, forced vital capacity, TLC, total lung capacity. *TLC was available for only 57 patients.
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pothesis, but most surprising, treatments with medica-
tions for obstruction were continued without clinical or
spirometric indications. Clearly such patients are exposed
to complications and costs of these therapies without
proven or plausible clinical benefits. Interestingly, the rate
of bronchodilator use before and after PFTs remained the
same in patients with COPD but decreased in those with
asthma. We suspect this is a statistical artifact related to
small sample size, nonetheless, it is a perseverant treat-
ment. However, it could suggest bronchodilator prescrip-
tion driven inappropriately by symptoms (i.e. dyspnea)
rather than objective physiologic abnormalities.
We did not examine why clinicians continue to pre-
scribe bronchodilators to patients whose function tests
did not show obstruction. However, this phenomenon
has been noted with other medications, most notably
acid-suppressors. For example, Slain and colleagues de-
monstrated that 32 of 121 adult patients admitted to
hospital reported taking either proton pump inhibitors
or histamine-blocking agents [16]. Similarly, 62 of 213
patients admitted to the University of Michigan Hospital
wards were receiving acid suppressors prior to admis-
sion, which increased to 152 of 213 during admissionFigure 3 Rate of treatment for obstruction in patients with
normal and restrictive, irreversible airflow obstruction (COPD)
and reversible obstruction (asthma) before (white bars) and
after (black bars) spirometry.(only 15 “indicated”), and 115 of 213 were discharged
on these medications [17]. The concept of “therapeutic
inertia” has been introduced to describe situations in
which clinicians fail to treat despite evidence of disease
[18]. It is possible that perseveration of non-indicated
acid suppression following hospitalization and broncho-
dilators without spirometric evidence of obstruction rep-
resent therapeutic inertia. Alternatively, perhaps this is a
result of treatment bias; for example, if patients expe-
rience a placebo effect, there may be an inclination to
continue a medication even without objective evidence
of improvement.
Medication errors are a common cause of harm in hos-
pitalized patients [19], and so appropriately the focus of
regulatory scrutiny [20]. While perseverant treatment of
our non-obstructed obese patients might be regarded as a
“medication error,” the genesis is probably more a malady
of “systems-based practice.” Too often disease entities are
entered in the medical record without meeting firm diag-
nostic criteria; sometimes on the basis of medications ad-
ministered presumptively [1-3]. Tests may be ordered but
not checked or carefully considered to ensure that treat-
ment regimens are appropriate [21]. Researchers are be-
ginning to develop taxonomies for these diagnostic and
therapeutic errors [21]. Arguably, the most important mes-
sage is that diagnoses should not be taken “at face value”Table 3 Adjusted odds ratios (ORs) and 95% confidence
intervals (CIs) for determinants of treatment for
obstructive airway disease among individuals with
normal and restrictive pattern in their PFTs
Spirometry Normal Restriction
Term OR 95% C.I. P-Value OR 95% C.I. P-Value
Age 1.00 0.95-1.04 0.87 1.10 1.00-1.21 0.05
BMI 0.97 0.90-1.05 0.51 1.10 0.98-1.22 0.10
CHF 2.24 0.16-30.66 0.54 0.18 0.02-1.87 0.15
DM 2.05 0.59-7.15 0.26 0.07 0.00-1.77 0.11
HTN 0.54 0.16-1.89 0.34 1.6x106 0.00-1x1012 0.96
Sex 1.43 0.42-4.89 0.57 2.36 0.24-23.72 0.46
Smoking 1.63 0.44-6.00 0.47 1.89 0.24-15.10 0.55
Adjustments were made for clinically relevant discriminators such as age,
body mass index (BMI), congestive heart failure (CHF), diabetes mellitus (DM),
hypertension (HTN), sex and smoking.
Table 4 Treatment individuals received before spirometry
Normal (62) Restriction (35) COPD (36) Asthma (11)
Inhaled Beta2-agonists 40.3% (25) 54.3% (19) 69.4% (25) 72.7% (8)
Inhaled corticosteroids 16.1% (10) 28.6% (10) 38.9% (14) 63.6% (7)
Inhaled Anticholinergic 14.5% (9) 14.3% (5) 33.3% (12) 9.1% (1)
Oral corticosteroids 8.1% (5) 14.3% (5) 13.9% (5) 9.1% (1)
Leukotriene antagonists 1.6% (1) 0 5.6% (2) 18.2% (2)
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ciliation of medications and diagnoses will promote safer,
patient-centered care. Specifically, our data combine with
other studies [9,22] to suggest that obesity is not – in
itself – an obstructive, but rather is more commonly a re-
strictive lung disease. While obstructions may occur dy-
namically with sleep in these patients, and some obese
patients may have true asthma or smoking-related obstruc-
tive disease, clinicians should exercise greater caution – via
confirmatory spirometry – before assigning or perpetuating
the label of obstructive lung disease to obese patients.
Mislabeling or misdiagnosis is not without risks and
costs, especially when (these) patients receive medications
that can cause complications but provide no proven bene-
fit (since they did not have obstruction). In addition to
tremor, tachycardia and hypokalemia, beta-agonists have
been associated with increased mortality in asthmatic pa-
tients, especially African Americans [23]. Anticholinergic
medications may also increase the risk of cardiovascular
death [24]. Inhaled and systemic corticosteroids are asso-
ciated with diabetes, hypertension, infection, pneumonia,
glaucoma, adrenal insufficiency, thrush, dysphonia, myo-
pathy, and cardiovascular events [25]. While we can find
no suggestion that obese patients are more vulnerable to
complications from these therapies, they could exacerbate
some diseases (e.g. hypertension, diabetes) that are more
common in the obese population.
Potential harm aside, our study has substantial financial
implications. 33% [26] of 246 million American adults
[27] are overweight or obese. If half of the 2% of those
with BMI > 22.1 kg/m2 who report asthma and take
bronchodilators [22] really don’t have reversible airflow
obstruction, substantial unnecessary cost (and risks) ac-
crues. At an average of $100/year (for generic albuterol)
[28], the total unnecessary cost – just for medication – is
over $80 million in the U.S. If more expensive medications
are administered – tiotropium and salmeterol/fluticasone
cost over $1000/year [29]– unnecessary cost increases
accordingly.
Our study has several limitations including its small sam-
ple size and sampling bias since our cohort represents only
the subgroup of obese patients referred for pulmonary
function testing. Since this study was conducted at only
one hospital, these results should be generalized cautiously.
But there is abundant evidence to suggest that incorrectdiagnosis (and subsequent treatment) of obstructive lung
disease occurs more globally [1-3,9]. Obese patients are
not unique; but rather our results emphasize that pulmo-
nary testing should be used to confirm or refute clinical
impressions, and to guide appropriate management. In
addition, lung volumes were not measured in 63% of pa-
tients. Vital capacity may differ from FVC in patients with
substantial airway obstruction [30]. While airway obstruc-
tion was rare in our study population, this methodologic
limitation, inherent in our retrospective study design, could
reduce the precision of our conclusions. Another limitation
of our study is that most (all but 2) individuals with normal
spirometry did not have metacholine challenge to rule
out bronchial hyper-responsiveness. In addition, although
patients were instructed not to use bronchodilators
for >12 hours, we did not ascertain the rate of compliance.
However, that does not undermine the importance of our
findings, since patients continued to receive bronchodila-
tors even after function tests failed to demonstrate airflow
obstruction. We cannot assert with certainty that bron-
chodilators were administered continuously/daily in all
patients without indications in the follow-up period (i.e. in
some the medications could have been stopped and later
restarted for a bronchospastic episode that was not docu-
mented in our medical records). It is also possible that
aerosols were administered to our patients for indications
other than obstructive symptoms e.g. to improve muco-
ciliary clearance [31]. However, since aerosols are seldom
used solely for this indication in clinical practice, it is not
unreasonable to assume that clinicians continued aerosols
for (misdiagnosed) obstructive lung disease.
Conclusion
In conclusion, 45.2% (28 of 62) of obese individuals with
normal PFTs and 60% (21 of 35) with restrictive pattern
received inappropriate treatment for obstructive lung
disease prior to PFTs. Fully a third (33.9%; 21 of 62) of
these obese patients with normal lung mechanics, and half
(51.4%; 18 of 35) with purely restrictive defects, continued
to receive inappropriate treatment after function testing.
A substantial number of individuals also received anticho-
linergics and inhaled and systemic steroids. Inappropriate
use of these medications exposes patients to risks of com-
plications and increases the cost of care with no proven or
theoretical benefit.
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